


## CLAIM AMENDMENTS

### Listing of Claims:

Claims 1-20 (canceled)

Claim 21 (previously presented): A crystalline free base of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile (citalopram), wherein the crystalline free base has a purity of at least 99.8% w/w and includes an impurity in amounts more than 0% w/w and no more than 0.2% w/w, the impurity having the formula



wherein Z is bromine or chlorine.

Claim 22 (previously presented): The crystalline free base of claim 21, wherein the crystalline free base is a crystalline precipitate.

Claim 23 (previously presented): The crystalline free base of claim 21, wherein the purity of the crystalline free base is at least 99.9% w/w.

Claim 24 (previously presented): A tablet comprising the crystalline free base of claim 21.

Claim 25 (previously presented): A tablet comprising the crystalline free base of claim 23.

Claim 26 (previously presented): A method of treating depression in a patient in need thereof comprising administering the crystalline free base of claim 21.

Claim 27 (previously presented): A method of treating depression in a patient in need thereof comprising administering the crystalline free base of claim 23.

Claim 28 (previously presented): A method of treating depression in a patient in need thereof comprising administering the tablet of claim 24.

Claim 29 (previously presented): A method of treating depression in a patient in need thereof comprising administering the tablet of claim 25.

Claim 30 (previously presented): The tablet of claim 24, wherein the crystalline free base of citalopram is racemic.

Claim 31 (previously presented): The tablet of claim 25, wherein the crystalline free base of citalopram is racemic.

Claim 32 (previously presented): The tablet of claim 24, further comprising a pharmaceutically acceptable adjuvant.

Claim 33 (previously presented): The tablet of claim 25, further comprising a pharmaceutically acceptable adjuvant.

Claim 34 (new): Crystalline citalopram free base.

Claim 35 (new): The crystalline citalopram free base of claim 34, wherein the crystalline citalopram free base is more than 99.8% w/w pure.

Claim 36 (new): The crystalline citalopram free base of claim 34, wherein the crystalline citalopram free base is more than 99.9% w/w pure.

Claim 37 (new): Crystalline citalopram free base having a melting point 90-93° C.

Claim 38 (new): A tablet comprising the crystalline citalopram free base of claim 34.

Claim 39 (new): A tablet comprising the crystalline citalopram free base of claim 37.

Claim 40 (new): A method of treating depression in a patient in need thereof comprising administering an effective amount of the crystalline citalopram free base of claim 34.

Claim 41 (new): A method of treating depression in a patient in need thereof comprising administering an effective amount of the crystalline citalopram free base of claim 37.